Peloton Therapeutics, Inc.
Clinical trials sponsored by Peloton Therapeutics, Inc., explained in plain language.
A biotech subsidiary of Merck, focused on developing oncology therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill shows promise for rare kidney cancer in VHL patients Results expected Apr 2027 (estimated)
-
Can a pill that starves tumors of oxygen help fight advanced cancer?
Disease control OngoingThis early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…
Phase 1 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill shows promise for rare kidney cancer in VHL patients
Disease control OngoingThis phase 2 trial is testing a daily pill called belzutifan in 50 people with VHL disease who have kidney cancer. The goal is to see if the drug can shrink tumors. Researchers are also monitoring how long any tumor shrinkage lasts and checking for side effects.
Phase 2 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC